Canada Pension Plan Investment Board Trims Stock Holdings in Insulet Corporation $PODD

Key Points

• The Canada Pension Plan Investment Board has significantly reduced its stake in Insulet Corporation by 66.8%, owning 15,870 shares worth approximately $4.17 million after selling 32,000 shares.
• Several institutional investors, including GAMMA Investing and American Century Companies, have increased their stakes in Insulet, reflecting growing confidence in the company.
• In recent analyst reports, Insulet's stock received multiple target price increases, with Oppenheimer raising their target to $324 and Wells Fargo enhancing it to $350, indicating a positive outlook.

Canada Pension Plan Investment Board trimmed its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 66.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,870 shares of the medical instruments supplier's stock after selling 32,000 shares during the quarter. Canada Pension Plan Investment Board's holdings in Insulet were worth $4,168,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. increased its position in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment increased its position in shares of Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after purchasing an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 target price (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada lifted their target price on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price for the company. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Stock Up 0.6%

Shares of PODD traded up $1.96 during midday trading on Friday, hitting $348.43. The company had a trading volume of 498,473 shares, compared to its average volume of 584,368. The company's 50-day simple moving average is $307.55 and its 200-day simple moving average is $289.86. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The firm has a market capitalization of $24.53 billion, a P/E ratio of 105.91, a P/E/G ratio of 2.92 and a beta of 1.36. Insulet Corporation has a 1 year low of $211.27 and a 1 year high of $350.00.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.